Karyopharm Therapeutics (NASDAQ:KPTI) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI - Free Report) in a report released on Thursday morning,Benzinga reports. They currently have a $7.00 price objective on the stock.

A number of other research firms also recently weighed in on KPTI. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $3.00 target price on shares of Karyopharm Therapeutics in a research report on Monday, February 10th. StockNews.com cut shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 22nd. Finally, Piper Sandler upped their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $5.00.

Karyopharm Therapeutics Price Performance

Karyopharm Therapeutics stock traded down $0.01 during mid-day trading on Thursday, reaching $0.60. 1,057,547 shares of the company traded hands, compared to its average volume of 787,132. The firm's 50 day moving average price is $0.66 and its 200 day moving average price is $0.76. The firm has a market capitalization of $75.54 million, a price-to-earnings ratio of -0.59 and a beta of 0.06. Karyopharm Therapeutics has a 52-week low of $0.53 and a 52-week high of $1.70.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. The business had revenue of $30.54 million during the quarter, compared to analysts' expectations of $30.29 million. On average, sell-side analysts anticipate that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Velan Capital Investment Management LP bought a new position in Karyopharm Therapeutics during the 4th quarter valued at about $27,000. Focus Partners Wealth bought a new position in Karyopharm Therapeutics during the 4th quarter valued at about $31,000. TD Waterhouse Canada Inc. bought a new position in Karyopharm Therapeutics during the 4th quarter valued at about $32,000. Two Sigma Advisers LP lifted its stake in Karyopharm Therapeutics by 145.5% during the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company's stock valued at $52,000 after acquiring an additional 45,400 shares during the period. Finally, Opti Capital Management LP bought a new position in Karyopharm Therapeutics during the 4th quarter valued at about $85,000. Institutional investors own 66.44% of the company's stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).